Studies have shown that exogenous administration of recombinant human IGF-I (51, 52) and IGF-I/IGFBP-3 complex (53–55) improved insulin sensitivity and decreased insulin requirements in both T1D and T2D patients. Here, IGF1 is linked to type 1 diabetes mellitus.